Peptides are food. The digestive system exists to break them into amino acids, which is why insulin and GLP-1 have always been injected. Two different engineering answers now get a GLP-1 receptor agonist through the mouth, and they work in almost opposite ways.
Answer one: protect the peptide (oral semaglutide)
Rybelsus co-formulates semaglutide with SNAC, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate. Buckley and colleagues showed how it works: the tablet erodes against the stomach wall, SNAC raises the pH in the small volume of fluid around it, which protects semaglutide from pepsin and keeps it in a form that crosses the gastric epithelium transcellularly. Absorption happens in the stomach, not the intestine, and is finished within about an hour (PubMed 30429357).
The cost is efficiency. Absolute bioavailability is around 0.4 to 1% (Rybelsus label). Where the injection delivers 0.25 to 2.4 mg per week, the tablets are dosed at 3, 7 and 14 mg daily for diabetes and 50 mg daily was tested for obesity. The dosing rules follow from the mechanism: an empty stomach, no more than 4 ounces of water, 30 minutes before food, drink or other oral medicines. Break the rules and the dose you absorb becomes unpredictable, mostly downward.
Answer two: do not use a peptide (orforglipron)
Orforglipron is a small molecule, not a peptide. It binds the GLP-1 receptor at a different site from the natural hormone and activates it, and it is absorbed through the intestine like most oral drugs, with no absorption enhancer and no food or water restrictions. Wharton and colleagues randomised 272 adults with obesity to orforglipron 12 to 45 mg daily or placebo for 36 weeks: weight change ranged from -9.4% to -14.7% across doses versus -2.3% on placebo, with gastrointestinal adverse events resembling the injectable class (PubMed 37351564). Phase 3 trials are digested at FormBlends Research as they publish; this page stays on mechanism.
What the trials showed
PIONEER 6. The cardiovascular safety trial required for approval randomised 3,183 adults with type 2 diabetes at high cardiovascular risk to oral semaglutide or placebo for a median 15.9 months. Major adverse cardiovascular events occurred in 3.8% versus 4.8%, hazard ratio 0.79 (95% CI 0.57 to 1.11), which met the noninferiority margin; cardiovascular death was lower on semaglutide (PubMed 31185157). The trial was sized for safety, not for proving benefit, and the confidence interval crosses 1.0, so it does not establish cardiovascular protection the way SELECT does for the injection.
OASIS 1. Oral semaglutide 50 mg daily versus placebo in 667 adults with overweight or obesity for 68 weeks: mean weight change -15.1% versus -2.4% (PubMed 37385278). That is in the same range as the 2.4 mg injection in STEP 1, which supports the point that once absorbed, the molecule does what the molecule does.
Why the route matters for mechanism
Two things differ mechanically between a daily tablet and a weekly injection of the same peptide, even at matched average exposure. The daily dose produces a smaller peak-to-trough swing, which might change the profile of nausea; and absorption variability day to day is larger, which is why the tablet's escalation takes 30 days per step. For a small molecule with no peptide-specific liabilities, manufacturing at scale is cheaper, which may matter more for access than any pharmacology.
What is debated
Whether orforglipron and other small-molecule agonists reproduce every effect of peptide agonists is not settled. Small molecules bind the receptor differently and may bias signalling differently; the clinical data so far show the expected weight and glucose effects with the expected gastrointestinal profile, and the cardiovascular and kidney outcome questions are for future trials. Compounded "oral semaglutide" products, including sublingual and lozenge formats, have no published bioavailability data of this kind, are not FDA approved and should not be assumed to deliver any particular dose.
Where to go next
- Trial digests: PIONEER 6 and the orforglipron ATTAIN-1 at FormBlends Research.
- Oral semaglutide dosing rules, missed-dose logic and cost: Semaglutide Hub.
Questions people ask
Why does the semaglutide tablet have to be taken on an empty stomach with a small sip of water?
Because it is absorbed through the stomach lining, not the intestine, and only while SNAC is holding the local pH up around the tablet. Food, a large volume of water or another tablet dilutes and displaces that microenvironment. The Rybelsus label specifies an empty stomach, no more than 4 ounces of plain water and at least 30 minutes before eating, drinking or other oral medicines (PubMed 30429357).
Is a tablet weaker than an injection?
Not at the receptor. Once absorbed, semaglutide is the same molecule. The tablet simply delivers a small and more variable fraction, which the dosing compensates for. OASIS 1 tested a 50 mg oral dose and produced weight loss in the same range as the 2.4 mg injection (PubMed 37385278).
Sources
- Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 2018. PubMed 30429357 Accessed September 4, 2026.
- Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER 6). N Engl J Med 2019. PubMed 31185157 Accessed September 4, 2026.
- Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). Lancet 2023. PubMed 37385278 Accessed September 4, 2026.
- Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med 2023. PubMed 37351564 Accessed September 4, 2026.
- Rybelsus (semaglutide tablets) prescribing information. Drugs@FDA, NDA 213051 Accessed September 4, 2026.
Canonical URL: https://formblendsscience.com/mechanisms/oral-glp1s. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.